PL1635875T3 - System dostarczania leków poprzez żelowanie w warunkach in-situ - Google Patents

System dostarczania leków poprzez żelowanie w warunkach in-situ

Info

Publication number
PL1635875T3
PL1635875T3 PL04756068T PL04756068T PL1635875T3 PL 1635875 T3 PL1635875 T3 PL 1635875T3 PL 04756068 T PL04756068 T PL 04756068T PL 04756068 T PL04756068 T PL 04756068T PL 1635875 T3 PL1635875 T3 PL 1635875T3
Authority
PL
Poland
Prior art keywords
delivery system
drug delivery
situ gelling
gelling drug
situ
Prior art date
Application number
PL04756068T
Other languages
English (en)
Inventor
Paul Ashton
Jianbing Chen
Dongling Su
Original Assignee
Psivida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida Inc filed Critical Psivida Inc
Publication of PL1635875T3 publication Critical patent/PL1635875T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04756068T 2003-06-26 2004-06-25 System dostarczania leków poprzez żelowanie w warunkach in-situ PL1635875T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48267703P 2003-06-26 2003-06-26
US57530704P 2004-05-28 2004-05-28
PCT/US2004/020369 WO2005002625A2 (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system
EP04756068A EP1635875B8 (en) 2003-06-26 2004-06-25 In-situ gelling drug delivery system

Publications (1)

Publication Number Publication Date
PL1635875T3 true PL1635875T3 (pl) 2009-03-31

Family

ID=33567657

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04756068T PL1635875T3 (pl) 2003-06-26 2004-06-25 System dostarczania leków poprzez żelowanie w warunkach in-situ

Country Status (16)

Country Link
US (4) US20050048123A1 (pl)
EP (2) EP2044959A1 (pl)
JP (1) JP5229768B2 (pl)
CN (2) CN1863557B (pl)
AR (1) AR044926A1 (pl)
AT (1) ATE410186T1 (pl)
CA (1) CA2530136C (pl)
CY (1) CY1108685T1 (pl)
DE (1) DE602004016995D1 (pl)
DK (1) DK1635875T3 (pl)
ES (1) ES2315680T3 (pl)
PL (1) PL1635875T3 (pl)
PT (1) PT1635875E (pl)
SI (1) SI1635875T1 (pl)
TW (1) TWI377958B (pl)
WO (1) WO2005002625A2 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
JP2007505932A (ja) * 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
JP4827626B2 (ja) * 2006-06-14 2011-11-30 キヤノン株式会社 被制御機器、遠隔制御システムおよび遠隔制御システムの制御方法、プログラム
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US20110059921A1 (en) * 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
JP2011513337A (ja) * 2008-04-18 2011-04-28 ウォーソー・オーソペディック・インコーポレーテッド 椎間板ヘルニアを治療するための方法および組成物
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB201014591D0 (en) * 2010-09-02 2010-10-13 Univ Nottingham Compositions
EP2643009A4 (en) * 2010-11-24 2015-04-01 Durect Corp COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
EP2736492A4 (en) * 2011-07-27 2015-06-17 Polypid Ltd MATRIX COMPOSITIONS FOR THE CONTROLLED RELEASE OF PEPTIDES AND POLYPEPTIDE MOLECULES
CA2901280A1 (en) * 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
CN107205940A (zh) 2014-12-15 2017-09-26 约翰霍普金斯大学 舒尼替尼制剂及其在治疗眼部疾病中的使用方法
EP3804698B1 (en) 2015-08-03 2024-01-31 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
TWI641387B (zh) * 2015-10-29 2018-11-21 逸達生物科技股份有限公司 安定性經改善之醫藥組成物
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
WO2018169934A1 (en) * 2017-03-14 2018-09-20 The Children's Hospital Of Philadelphia Cleavable esters for nanocarrier-based cancer therapy
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
US11530240B2 (en) 2017-06-09 2022-12-20 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
BR112019026225A2 (pt) * 2017-06-13 2020-06-30 The University Of British Columbia composições de pasta polimérica para liberação de fármacos
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
UY38386A (es) * 2018-09-25 2020-04-30 Tolmar Int Ltd Sistema de suministro de polímero líquido para la administración prolongada de fármacos
US12409153B2 (en) 2018-11-02 2025-09-09 Amaterasu Lifesciences Llp Liquid injectable composition
WO2020177830A1 (en) 2019-03-05 2020-09-10 El Sebaei Fatma Long lasting biodegradable polymer based in-situ forming implant for treatment of bone injuries
CA3133348A1 (en) * 2019-03-15 2020-09-24 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
GB202000714D0 (en) * 2020-01-17 2020-03-04 Ucl Business Biomaterials
CN111374940A (zh) * 2020-04-13 2020-07-07 宁波赛缪斯生物科技有限公司 一种可原位聚合的胶原注射剂及其使用方法
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
US20240277654A1 (en) 2021-07-06 2024-08-22 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
US12559880B2 (en) 2022-03-17 2026-02-24 Haier Us Appliance Solutions, Inc. Dryer appliance and infuser assembly
CN119258216A (zh) * 2023-07-05 2025-01-07 沈阳兴齐眼药股份有限公司 眼用药物组合物、其制备方法、含其的眼用药盒及应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
JPS59110607A (ja) 1982-12-17 1984-06-26 シ−トン・カンパニ− 医薬化粧品用軟質連続フイルム
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
AU3432689A (en) 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5681964A (en) 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
CZ282889B6 (cs) * 1991-12-17 1997-11-12 Procter And Gamble Pharmaceuticals, Inc. Použití difosfonátů a parathormonu pro výrobu léčiva, které se používá pro léčení osteoporosy
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
ES2258495T3 (es) * 1994-04-08 2006-09-01 Qlt Usa, Inc. Composiciones de administracion liquida de farmacos.
GB9409281D0 (en) 1994-05-10 1994-06-29 Svedman Paul Transdermal device
US5607686A (en) 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
JP2002512597A (ja) 1996-12-20 2002-04-23 アルザ コーポレイション 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6102887A (en) * 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use
AU765909C (en) 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
NZ515911A (en) 1999-06-04 2004-02-27 Alza Corp Implantable gel compositions and method of manufacture
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
CN1283215C (zh) * 2000-06-28 2006-11-08 A·J·舒克拉 生物活性物质的可生物降解载体和释放系统
CN1206001C (zh) * 2000-06-28 2005-06-15 A·J·舒克拉 生物可降解载体和生物可降解传输系统
AU2000202A (en) * 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
CN1520297A (zh) 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
DK3025726T3 (da) 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
JP5305135B2 (ja) 2008-08-05 2013-10-02 株式会社リコー 潤滑剤薄膜化装置、並びに、これを備える画像形成装置及びプロセスカートリッジ

Also Published As

Publication number Publication date
CN1863557A (zh) 2006-11-15
SI1635875T1 (sl) 2009-04-30
JP2007524628A (ja) 2007-08-30
US9566336B2 (en) 2017-02-14
EP1635875A2 (en) 2006-03-22
CA2530136C (en) 2012-10-16
US20130101656A1 (en) 2013-04-25
US20050048123A1 (en) 2005-03-03
CN1863557B (zh) 2010-06-16
US20140336278A1 (en) 2014-11-13
DE602004016995D1 (de) 2008-11-20
EP1635875B1 (en) 2008-10-08
WO2005002625A2 (en) 2005-01-13
ES2315680T3 (es) 2009-04-01
AR044926A1 (es) 2005-10-12
CY1108685T1 (el) 2014-04-09
CN101862455A (zh) 2010-10-20
CA2530136A1 (en) 2005-01-13
TWI377958B (en) 2012-12-01
EP2044959A1 (en) 2009-04-08
WO2005002625A3 (en) 2005-04-21
JP5229768B2 (ja) 2013-07-03
TW200514581A (en) 2005-05-01
DK1635875T3 (da) 2009-01-12
PT1635875E (pt) 2008-12-09
US20110165242A1 (en) 2011-07-07
EP1635875B8 (en) 2008-12-24
ATE410186T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
SI1635875T1 (sl) Sistem za dajanje zdravila, ki se gelira in situ
PL1631255T3 (pl) System dostarczania leków
GB2421689B (en) Drug delivery system
PL372323A1 (pl) Wszczepiany zespół do podawania leków
IL174690A0 (en) Enhanced drug delivery
PL376169A1 (pl) Układ dostarczania leku
AU2003299849A8 (en) Drug delivery apparatus
IL174748A0 (en) Nanoparticles for drug delivery
HUP0203102A3 (en) Bioadhesive drug delivery system
GB2404867B (en) Delivery devices
GB2385273B (en) Drug delivery device
IL174396A0 (en) Oral drug delivery system
AU2003269744A8 (en) Oral osmotic controlled drug delivery system
AU2003285550A1 (en) Drug delivery system
EP1509612A4 (en) TRANSCELLULAR DRUG DISPENSING SYSTEM
GB0401008D0 (en) Drug delivery system
EP1732555A4 (en) SYSTEM FOR ADMINISTERING AN OPIOID
TWI350189B (en) Implantable drug delivery system
IL163614A0 (en) System for transvaginal drug delivery
IL156837A0 (en) Topical drug delivery system
GB0329141D0 (en) Drug delivery
GB0311084D0 (en) Drug delivery
GB0327409D0 (en) Delivery system
HK1091710A (en) Pharmaceutical delivery system
GB0217478D0 (en) Multiple-therapy drug delivery